Vitamin Shoppe’s “Overweight” Rating Reaffirmed at JPMorgan Chase & Co. (VSI)
Vitamin Shoppe (NYSE:VSI)‘s stock had its “overweight” rating restated by research analysts at JPMorgan Chase & Co. in a report released on Wednesday. They currently have a $49.00 price target on the stock, down from their previous price target of $54.00. JPMorgan Chase & Co.’s price objective would indicate a potential upside of 28.58% from the company’s current price.
Shares of Vitamin Shoppe (NYSE:VSI) traded down 5.06% during mid-day trading on Wednesday, hitting $38.11. 1,332,410 shares of the company’s stock traded hands. Vitamin Shoppe has a one year low of $38.78 and a one year high of $55.20. The stock’s 50-day moving average is $43.38 and its 200-day moving average is $44.63. The company has a market cap of $1.154 billion and a price-to-earnings ratio of 18.49. Vitamin Shoppe also was the target of unusually large options trading on Tuesday. Stock traders purchased 255 put options on the company. This is an increase of 111% compared to the typical volume of 121 put options.
Vitamin Shoppe (NYSE:VSI) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.62 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.63 by $0.01. The company had revenue of $306.20 million for the quarter, compared to the consensus estimate of $306.09 million. During the same quarter last year, the company posted $0.60 earnings per share. Vitamin Shoppe’s revenue was up 9.6% compared to the same quarter last year. Analysts expect that Vitamin Shoppe will post $2.34 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Longbow Research reiterated a “buy” rating on shares of Vitamin Shoppe in a research note on Wednesday. They now have a $55.00 price target on the stock, down previously from $59.00. Separately, analysts at Morgan Stanley cut their price target on shares of Vitamin Shoppe to $49.00 in a research note on Wednesday. Finally, analysts at Goldman Sachs downgraded shares of Vitamin Shoppe from a “conviction-buy” rating to a “buy” rating in a research note on Wednesday. Five investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $50.47.
Vitamin Shoppe, Inc is a specialty retailer and direct marketer of vitamins, minerals, herbs, specialty supplements, sports nutrition and other health and wellness products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.